Day: July 3, 2021

SPRINGDALE, Ark., July 03, 2021 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), is voluntarily recalling approximately 8.5 million pounds of frozen, fully cooked chicken. Tyson has been working closely with the U.S. Department of Agriculture on this recall, and while there is no conclusive evidence that the products were contaminated at the time of shipment, the voluntary recall is being initiated out of an abundance of caution. The affected products were produced at one plant located in Dexter, Missouri, between December 26 of 2020 and April 13 of 2021 and distributed to foodservice and retail customers nationwide and Puerto Rico. They are being recalled as a precaution due to possible exposure to Listeria monocytogenes, a harmful bacteria.   “We’re committed to providing safe, healthy food that people rely on every day,” said...

Oslo, 3 July 2021 Reference is made to the announcements by Ensurge Micropower ASA (the “Company”) on 20 May 2020 and 19 August 2020, regarding the Extraordinary General Meetings where the shareholders resolved to issue warrants to participants in two separate Private Placements and Subsequent Offerings of shares, and to the announcements on 30 June 2020 and 16 September 2020 regarding the results of such Subsequent Offerings. The Company has received further notices of exercise for a total of 4,362,682 Warrants B and a total of 289,416,821 Warrants C and has subsequently resolved to increase the Company’s share capital by NOK 32,315,745.33 in connection with the issuance of shares upon said exercises. Both Warrants B and Warrants C have an exercise price of NOK 0.25 per share. Upon registration of this share capital...

— ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer — Estimated OS at 12 months of 76% — ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET BURLINGAME, Calif., July 03, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the presentation of updated clinical data from its ongoing ASPEN-01 trial evaluating ALX148 in combination with trastuzumab and chemotherapy for the treatment of gastric or gastroesophageal junction cancer (“GC”). The new results, shared in an oral presentation at the 23rd World Congress on Gastrointestinal Cancer, show that ALX148 in combination with trastuzumab and chemotherapy is...